Journal List > Korean J Hematol > v.44(1) > 1032837

TOOLS
Yoon, Kim, Kim, Kim, Kim, Park, Lee, Lee, Bae, Lee, Won, Park, and Hong: Initial Therapy with High-Dose Dexamethasone for Patients with Idiopathic Thrombocytopenic Purpura
Original Article

Korean J Hematol 2009;44(1):22-27.

Published online: 20 March 2009

DOI: https://doi.org/10.5045/kjh.2009.44.1.22

Initial Therapy with High-Dose Dexamethasone for Patients with Idiopathic Thrombocytopenic Purpura

Jin Ah Yoon, M.D.1, Chan Kyu Kim, M.D.2, Se Hyung Kim, M.D.2, Kyung Ha Kim, M.D.2, Hyun Jung Kim, M.D.2, Sung Kyu Park, M.D.2, Sang Chul Lee, M.D.2, Nam Su Lee, M.D.2, Sang Byung Bae, M.D.2, Kyu Taek Lee, M.D.2, Jong Ho Won, M.D.2, Hee Sook Park, M.D.2, Dae Sik Hong, M.D.2,

1Department of Internal Medicine, Bucheon, Korea

2Division of Hematology and Oncology, College of Medicine, Soonchunhyang University, Bucheon, Korea

Correspondence to：Dae Sik Hong, M.D., Ph.D. Division of Hematology and Oncology, College of Medicine, Soonchunhyang University 1174, Jung-dong, Wonmi-gu, Bucheon 420-767, Korea Tel: ＋82-32-621-5184, Fax: ＋82-32-621-5016 E-mail: dshong@schbc.ac.kr

Received 14 April 2008       Revised 10 March 2009       Accepted 15 March 2009

Copyright © 2009 Korean Society of Hematology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Corticosteroids have been widely used for treatingidiopathic thrombocytopenic purpura (ITP) as a first-line treatment. Several different pulsed high-dose dexamethasone therapies for adult ITP have been reported on. We assessed the effectiveness of a single course of high dose dexamethasone as first-line treatment for adult patients with ITP.

Methods

The subjects of the study were previously untreated adult patients with newly diagnosed ITP and who had a platelet count of less than 20,000/μL or a platelet count less than 50,000/μL. High-dose dexamethasone at a dose of 40mg/day for four consecutive days was given orally. A response was defined as an increase in the platelet count of at least 30,000/μL and a platelet count of more than 50,000/μL by day 10 after the initial treatment. A sustained response was defined as a platelet count of more than 50,000/μL that was maintained for six months after the initial treatment.

Results

Twenty two patients were eligible. The median platelet count before treatment was 19,000/μL. Seventeen patients (77%) among the 22 patients achieved an initial response by day 10: the mean platelet count 10 days after the initial treatment was 144,000/μL (range: 51,000 to 428,000/μL). Among the patients with a response, 4 (23.5%) had a sustained response, and the other 13 (76.5%) relapsed within six months. All the patients well tolerated the high-dose dexamethasone treatment.

Conclusion

A single course of high-dose dexamethasone is effective as an initial treatment for adults ITP patients, although the response duration is short. To maintain the response, repeated high-dose dexamethasone treatment may be needed or other alternative therapies can be considered.

Keywords: Idiopathic thrombocytopenic purpura (ITP), Dexamethasone, Treatment

References

1. McMillan R. Antigen-specific assays in immune thrombocytopenia. Transfus Med Rev. 1990; 4:136–43.
crossref
2. van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood. 1982; 59:23–6.
crossref
3. McVerry BA. Management of idiopathic thrombocytopenic purpura in adults. Br J Haematol. 1985; 59:203–8.
crossref
4. Geroge JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88:3–40.
5. George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994; 331:1207–11.
crossref
6. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997; 126:307–14.
crossref
7. Bellucci S, Charpak Y, Chastang C, Tobelem G. Low doses v conventional doses of corticoids in immune thrombocytopenic purpura (ITP): results of a randomized clinical trial in 160 children, 223 adults. Blood. 1988; 71:1165–9.
crossref
8. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346:995–1008.
crossref
9. Mazzucconi MG, Francesconi M, Fidani P, et al. Treatment of idiopathic thrombocytopenic purpura (ITP): results of a multicentric protocol. Haematologica. 1985; 70:329–36.
10. Apostolidis J, Tsandekidi M, Kousiafes D, et al. Short-course corticosteroid-induced pulmonary and apparent cerebral aspergillosis in a patient with idiopathic thrombocytopenic purpura. Blood. 2001; 98:2875–7.
crossref
11. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001; 97:2549–54.
crossref
12. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994; 330:1560–4.
crossref
13. Khouri I, Tuan B, Grant K. Immune thrombocytopenic purpura. N Engl J Med. 2002; 347:449–50.
crossref
14. Warner M, Wasi P, Couban S, Hayward C, Warkentin T, Kelton JG. Failure of pulse high-dose dexamethasone in chronic idiopathic immune thrombocytopenia. Am J Hematol. 1997; 54:267–70.
crossref
15. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003; 349:831–6.
crossref
16. Pamuk GE, Pamuk ON, Baslar Z, et al. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol. 2002; 81:436–40.
17. George JN. Initial management of adults with idiopathic (immune) thrombocytopenic purpura. Blood Rev. 2002; 16:37–8.
crossref
18. Wali YA, Al Lamki Z, Shah W, Zacharia M, Hassan A. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 2002; 19:329–35.
crossref
19. Schiavotto C, Ruggeri M, Castaman G, Rodeghiero F. High-dose dexamethasone in adult refractory idiopathic thrombocytopenic purpura. Br J Haematol. 1996; 93:491–2.
20. Demiroğlu H, Dündar S. High-dose pulsed dexamethasone for immune thrombocytopenia. N Engl J Med. 1997; 337:425–7.
crossref
22. Caulier MT, Rose C, Roussel MT, Huart C, Bauters F, Fenaux P. Pulsed high-dose dexamethasone in refractory chronic idiopathic thrombocytopenic purpura: a report on 10 cases. Br J Haematol. 1995; 91:477–9.
crossref
23. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD- DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007; 109:1401–8.

Fig. 1.
Treatment protocol and results in 22 patients with newly diagnosed idiopathic thrombocytopenic purpura.
kjh-44-22f1.tif
Table 1.
Comparison of clinical and laboratory variables between responder and unresponder∗†
Variable Responder (17 patients) Unresponder (5 patient) P-value
Age (yr) 36.59±16.2 59.20±22.1 0.065
Sex (no.)     0.781
Male 8 2  
Female 9 3  
Platelet count (per μL)†      
Pretreatment 20,000 14,000 0.969
Day 2 45,000 28,000 0.327
Day 3 77,000 39,000 0.005
Day 4 109,000 41,000 0.003
Day 10 144,000 11,000 0.001

∗ Plus-minus values are means±SD,

† Platelet counts are median.

Table 2.
Comparison of clinical and laboratory variables between sustained response and relapse among the 17 patients with an initial response∗
Variable Sustained response (4 patients) Relapse (13 patient) P value
Age (yr) 44.50±22.87 34.15±13.90 0.893
Sex (no.)     0.394
Male 2 6  
Female 2 2  
Platelet count (per μL)†
Pretreatment 26,500 18,000 0.720
Day 2 54,000 28,000 0.125
Day 3 113,500 63,000 0.079
Day 4 149,000 109,000 0.245
Day 10 191,000 115,000 0.236
Day 30 207,000 120,500 0.034

∗ Plus-minus values are means±SD,

† Platelet counts are median.

TOOLS
Similar articles